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Abstract: Vitamin D is a secosteroid hormone regulating the expression of almost 900 genes, and it
is involved in the regulation of calcium and phosphate metabolism, immune response, and brain
development. Low blood vitamin D levels have been reported in patients affected by various diseases.
Despite a large amount of literature data, there is uncertainty surrounding the role of vitamin D as
a serum biomarker in Alzheimer’s disease (AD) and Parkinson’s disease (PD). Indeed, the lack of
internationally recognized 25(OH)D3 reference measurement procedures and standard materials
in the past led to unstandardized serum total 25(OH)D3 results among research and clinical care
laboratories. Thus, most of the literature studies reported unstandardized data, which are of little
use and make it difficult to draw conclusions of the role of vitamin D in AD and PD. This review
summarizes the extra-skeletal actions of vitamin D, focusing its role in immunomodulation and brain
function, and reports the issue of lacking standardized literature data concerning the usefulness of
vitamin D as a biomarker in AD and PD.
Keywords: vitamin D; immune system; brain function; 25(OH)D3; Alzheimer’s disease;
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1. Introduction
In the early 1920s, amid the industrial revolution, McCollum discovered that fish oil containing
a high amount of vitamin D could treat rickets [1]. Since then, skeletal health and bone metabolism
have been invariably associated with vitamin D status. Nonetheless, over the past two decades,
the literature in the field of vitamin D grew fast, showing a multifaceted role of the nutrient in
modulating many processes of body homeostasis. Vitamin D is regarded as a neurosteroid regulating
immunomodulation and brain development and function in adulthood [2,3]. Vitamin D has been long
studied in several pathologies either as a risk factor for disease development or a disease severity
biomarker. However, there is no consensus on the optimal vitamin D status due to the lack of
standardized measurement procedures and materials, as shown for other analytes [4–6]. The current
paper summarizes the extra-skeletal actions of vitamin D, focusing on the modulation of immune
response and brain activities. Further, it mentions the issue of the lack of vitamin D standardized data
in the literature, especially concerning neurodegenerative diseases.
2. Vitamin D Synthesis and Metabolism
Vitamin D includes two natural compounds: Vitamin D2, which is obtained by the diet,
and vitamin D3, which derives both from the diet and endogenous synthesis. Ultraviolet B rays
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(295–310 nm) transform the cutaneous precursor 7-dehydrocholesterol into vitamin D3 (cholecalciferol),
which requires two sequential hydroxylations to form the active vitamin D3. The first hydroxylation
produces 25(OH)D3 in the liver through the action of 25-hydroxylase. The second hydroxylation is
carried out by 1-α-hydroxylase forming 1,25(OH)2D in the kidney, prostate, placenta, lung, brain,
and immune cells, all of which express 1-α-hydroxylase [7]. It is worth mentioning that kidney
1-α-hydroxylase is regulated by parathyroid hormone (PTH) [8], and active vitamin D produced plays
a crucial role in calcium/phosphorus homeostasis, while the extra-renal enzyme is tightly regulated
by pro-inflammatory cytokines [9], and active vitamin D produced regulates cell proliferation and
differentiation in many tissues and organs as well as immune cells [10]. All enzymes participating
in vitamin D metabolism belong to the cytochrome P450 (CYP450) family, which is also involved in
liver drug catabolism and oxidation/reduction reactions [11]. Other pathways of vitamin D activation
are initiated by CYP11A1, leading to the production of non- or low-calcemic actions and lumisterol
activation [12–15]. CYP11A1 is known to catalyze the first step of steroidogenesis, converting cholesterol
to pregnenolone, but 7-dehydrocholesterol, ergosterol, lumisterol 3, and vitamins D3 and D2 are
substrates for this enzyme as well.
Vitamin D receptors encompass a nuclear receptor, vitamin D Receptor (VDR), and a surface
receptor, membrane-associated rapid response steroid binding (MARRS), also known as protein
disulfide isomers family A members 3 (PDIA3). Other vitamin D receptors include RORα and RORγ,
which are expressed in the skin, and aryl hydrocarbon receptor (AhR) [16–18].
Upon binding both VDR and MARRS, genomic and non-genomic actions are carried out by
1,25(OH)2D. The former include genes transcription activation (cathelicidin, nerve growth factor—NGF)
and suppression (1-α- hydroxylase, PTH), the latter comprise the regulation of the activity of some
proteins (p38 MAP kinase, protein kinase C, adenylyl cyclase, phospholipase C) and the intracellular
Ca2+ influx [19,20]. The interaction between 1,25(OH)2D and PDIA3 receptor is deemed to mediate
vitamin D brain action, while the modulation of the immune response depends on the interaction
with VDR [21].
3. Vitamin D Immunomodulatory Activities
Active vitamin D modulates the immune response by interacting with innate and adaptive
immune system cells, regulating the expression of cytokines, since macrophages, dendritic cells,
and activated B and T lymphocytes express 1α-hydroxylase and VDR [22]. NF-kB activity is inhibited
by 1,25(OH)2D in lymphocytes, NF-kB being a transcription factor involved in pro-inflammatory
cytokines synthesis [23,24]. The antigen presenting ability of dendritic cells, as well as their survival,
is diminished by vitamin D [25,26]. Importantly, T-helper (Th) cells’ balance is influenced by vitamin
D. Th cells include Th1, Th2, and Th17. Vitamin D inhibits the production of Th1 and Th17 cytokines
(IFN-γ, TNF-α, IL-17, IL-21, IL-12, IL-1, IL-2, IL-23, and IL-17) and increases Th2 cytokines synthesis
(IL-10, IL-4), thus enhancing Th2 cells differentiation [27]. Further, active vitamin D fosters the
differentiation of T-regulatory (Treg) cells, increasing the production of Treg cytokines (including
FoxP3) [10]. By modulating Th cells balance and enhancing the development of Treg, active vitamin D
contributes to protection against pathogens [28].
Finally, active vitamin D induces the production of antimicrobial peptides, including cathelicidin
and defensin [29]. Overall, the immunomodulatory action of vitamin D ends in an increase of the
innate immune response antimicrobial activity and the decrease of the adaptive immune response
proinflammatory action.
4. Vitamin D as a Light-Dependent Control System of Immunity
The action of vitamin D on immune response should be interpreted within the context of body’s
homeostatic regulation, taking into account the role of the interactions between neuroendocrine and
immune systems in regulating such homeostatic balance [30,31]. In this scenario, the operation of the
three main mechanisms controlling the immune response, including vitamin D, vagus nerve activity,
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and melatonin, has emerged [32,33]. Within the context of homeostatic regulation, a significant role is
played by circadian rhythms, which depend on many tissue-specific, cellular clocks, and is strictly
influenced by exogenous rhythms, like light-dark rhythm, due to a synchronization operated by the
suprachiasmatic nucleus of the hypothalamus [34]. Research in the field of circadian rhythm has shown
that this is related to the immune response [34]. It has been suggested that each of these immune
response control systems could be a part of a light-dependent immunity regulation system [35]. Indeed,
light inhibits both melatonin production and the activity of vagus nerve via suprachiasmatic nucleus,
while inducing the production of vitamin D. While both melatonin and vagus nerve reach the peak of
expression and activity in the night, the maximum vitamin D synthesis is obtained during the day.
This might suggest that the immune response control systems work alternatively in a light-dependent
manner, assuring a controlled immune system activity cyclically over 24 h.
5. Vitamin D and Cerebral Activity
Many areas of the brain, including amygdala, hippocampus, thalamus, cortex, and substantia
nigra, express both VDR and 1α-hydroxylase [36]. Multiple lines of evidence show that vitamin D
can be actively synthesized by neurons and microglia, which use the active hormone to regulate cell
proliferation, differentiation, and survival [37]. It has been documented that vitamin D can influence
fundamental processes for brain development in the embryonic brain, including synaptic plasticity and
cytoskeleton maintenance [38,39]. Almeras et al. demonstrated that prenatal vitamin D deficiency alters
the expression of drebrin and growth-associated protein-43 (GAP-43), two synaptic plasticity-related
proteins whose alterations have been reported in schizophrenia [40]. Drebrin is an actin-binding
protein being present in both the developmental and adult brain in two isoforms, drebrin E and drebrin
A, respectively. Drebrin A expression correlates to synapse formation, and its dysregulation could
give a reason for dendritic spine alteration observed in schizophrenia patients [41]. GAP-43 controls
axonal growth and neural circuits arrangement and stabilization, thus playing a crucial role in synaptic
plasticity. It has been suggested that vitamin D deficiency in the developmental brain could be part of
the pathophysiology of schizophrenia through the deregulation of drebrin and GAP-43 [42].
Vitamin D has been shown to upregulate neurotrophic factors, including nerve growth factor
(NGF), glial-derived nerve growth factor (GDNF), and neurotrophin 3 (NTF3) [37]. NGF is a pivotal
molecule driving neuronal survival of hippocampal and cortical neurons. Gezen-Ak et al. documented
that vitamin D regulates NGF release and prevents cytotoxicity in primary hippocampal neuron
cultures [43]. GDNF and its receptor proto-oncogene tyrosine-protein kinase receptor Ret (C-Ret) have
been recently shown to be directly regulated by vitamin D in SH-SY5Y cells [44]. This result confirms
previous findings on the role that vitamin D plays in the differentiation of dopaminergic neurons by
influencing critical enzymes involved in dopamine production pathways, such as tyrosine hydroxylase
and catechol-O-methyltransferase [45].
Finally, vitamin D helps neuroprotection through several mechanisms. It prevents excitotoxicity
injury caused by a sudden increase in cytoplasmic Ca2+, up-regulates the synthesis of parvalbumin and
calbindin, and down-regulates L-type voltage-gated calcium channels (L-VGCCs) [46]. The hormone
exerts anti-inflammatory activities, inhibits the inducible synthesis of nitric oxide (iNO), and increases
γ-glutamyl-transpeptidase in glutathione pathways, reducing oxidative burden within neurons
and microglia [47,48].
Due to the evidence mentioned above, vitamin D is deemed to contribute to the connectivity of
the ventral tegmental area-accumbens nucleus-prefrontal cortex circuit and the nigro-striatal circuit,
which are dopaminergic neural circuits involved, respectively, in reward-dependent and motor
behavior [49,50]. Further, the influence of vitamin D status in neurocognition has been suggested,
also due to the wide presence of VDR and 1α-hydroxylase within the brain areas involved in cognitive
processes like complex planning and formation of new memories [51,52].
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6. Lacking 25(OH)D3 Standardized Data: The Case of Alzheimer’s Disease and Parkinson’s Disease
The best biomarker for vitamin D status is 25-hydroxyvitamin D (25(OH)D3). Low 25(OH)D3
serum levels in neurological, autoimmune and infectious diseases are a common finding [53–56].
Together with cardiovascular and inflammatory markers, 25(OH)D3 has been proposed as a serum
biomarker in neurodegenerative disorders [57–65]. It has also been proposed as a serum biomarker
of disease severity during infections, along with well-established biomarkers [66–69]. However,
there was a lack of standardization in 25(OH)D3 measurement procedures and materials in the
past, leading to an elusive definition of optimal vitamin D status, as shown for other analytes [4–6].
Standardization process aligns laboratories and assays with the “true” 25(OH)D3 concentration,
based on internationally recognized reference procedures and materials, regardless of the location,
time, and system. The Vitamin D Standardization Program (VDSP) was recently funded to reduce
total 25(OH)D3 measurement analytical variability, encouraging manufacturers and research and
routine clinical care laboratories to use methods and materials traceable to NIST RMPs and standard
reference materials (SRMs) [6]. However, the lack of standardization of 25(OH)D3 measurement has
hampered the development of consensus guidelines defining vitamin D deficiency, insufficiency and
sufficiency. This yields to the difficulty in interpreting a large amount of literature data available, since
the majority of the studies in the field of vitamin D mainly report unstandardized results [6]. This is
especially apparent in relation to the studies evaluating 25(OH)D3 serum levels in AD. Substantial
evidence shows that vitamin D deficiency is associated with cognitive impairment [70–73], and an
association between low 25(OH)D3 serum levels and the risk of developing AD has been reported
by several authors [54,74–77]. However, many studies, including those with a long-term follow-up
longitudinal design, reported conflicting results [78–80]. Discrepancies among the findings can also be
explained by variation across the cut-off used to define vitamin D deficiency [43]. A large meta-analysis
also reported substantial heterogeneity among the studies reviewed due to differing vitamin D assay
methods used [81]. The main concern about most of the studies is that they report unstandardized
data, as only a few authors certified the use of internationally recognized procedures and materials.
Thus, the role of 25(OH)D3 as a serum biomarker in AD remains uncertain, although broad literature
data are available.
The same scenario can be observed when evaluating the studies on the role of vitamin D in
Parkinson’s disease (PD). Although low 25(OH)D3 serum levels have been largely reported among PD
patients [82–84], it should be noted that the studies reporting the use of certified materials were few
and with small sample size [85]. An association between 25(OH)D3 serum levels and PD severity have
been also reported, but here again the sample size was too small to give strength to study results [86].
Further, the meta-analysis performed in this field should be interpreted with caution due to the high
heterogeneity among the assay methods used in the studies reviewed [51]. As in the case of AD,
only a few studies evaluating relatively small samples reported standardized data, and meta-analysis
are of little use; therefore, available data do not support a role for serum 25(OH)D3 in PD.
Liquid chromatography-mass spectrometry (LC-MS) based assays have been developed to
measure other metabolites and molecules, including vitamin D2 and vitamin D3 forms of 1,25(OH)2D3,
3-epi-25(OH)D3, 24,25 (OH)2D3, vitamin D-binding protein (DBP) and free/bioavailable 25(OH)D3,
to be used as potential biomarkers for vitamin D status [87]. NIST has also developed RMPs for
25(OH)D2, and 24R,25(OH)2D3, and disseminated serum-based SRMs with values assigned for
25(OH)D2, 25(OH)D3, 3-epi-25(OH)D3, and 24R,25(OH)2D3 [88]. However, their usefulness in AD and
PD has not been thoroughly evaluated yet.
7. Summary and Conclusions
Vitamin D plays a key role in various physiological processes, ranging from the modulation of the
immune response to the regulation of brain development and activities in adulthood. Hence, vitamin D
has been long studied in many pathological conditions, either as a risk factor or a serum biomarker
for disease severity. Unfortunately, the lack of 25(OH)D3 measurement standardization in the past
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hampered the development of consensus guidelines defining vitamin D deficiency, insufficiency,
and sufficiency, thus leading to the difficulty in interpreting a considerable volume of literature data
available. This is the case for AD and PD, for which vitamin D could represent a good candidate as
a serum biomarker, but, despite a growing body of literature data, the usefulness of the studies is
weakened by the discrepancies in the assay methods and cut-offs used. Standardized data are required
to perform meaningful meta-analysis, supporting reliable conclusions on the potential role of vitamin
D in AD and PD.
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